Keyphrases
Overall Survival
100%
Monoclonal Antibody
52%
In Cancer
49%
Confidence Interval
45%
Prognostic Value
37%
Chemotherapy
37%
Chemotherapy Side Effects
36%
Patient Education
36%
Hazard Ratio
35%
Economic Burden
30%
Clinical Benefit
30%
Surgical Treatment
30%
Molecular Targeted Agents
30%
Splenosis
30%
Behavioral Health
30%
DNA Damage Response Genes
30%
Breast Cancer
30%
Sarcoma Resection
30%
Hereditary Angioedema
30%
Chemotherapy Response
30%
Advanced Urothelial Carcinoma
30%
Hematological Malignancies
30%
DNA Damage Response
30%
Creative Writing
30%
Genetic Modification
30%
Intraoperative Radiation Therapy
30%
Pounding
30%
Stage IV Breast Cancer
30%
Amazon Echo
30%
Oncology Patients
30%
Randomized Clinical Trial
30%
Molecular Therapy
30%
Systemic Therapy
30%
Epidermal Growth Factor Receptor
30%
Human Epidermal Growth Factor Receptor 2 (HER2)
30%
Non-small Cell Lung Cancer (NSCLC)
30%
Brochure
30%
Show Trials
30%
Preoperative Chemotherapy
30%
Simple Technique
30%
Acute Lymphoblastic Leukemia
30%
Bladder Cancer
30%
Postoperative Therapy
30%
Angioedema
30%
Hormone Receptor
30%
Angiotensin-converting Enzyme Inhibitor (ACEi)
30%
Metastatic Breast Cancer
30%
Cancer Institute
25%
Penn State
25%
Number-needed-to-treat
24%
Medicine and Dentistry
Malignant Neoplasm
95%
Overall Survival
87%
Breast Cancer
67%
Immunotherapy
65%
Surgery
60%
Urothelial Cancer
60%
Oncology
50%
Hazard Ratio
45%
Monoclonal Antibody
36%
Side Effect
35%
Hematologic Malignancy
30%
Randomized Clinical Trial
30%
Spleen Injury
30%
Writing
30%
Gamma Urogastrone
30%
Epidermal Growth Factor Receptor 2
30%
Health Care Cost
30%
Hormone Receptor
30%
DNA Damage Response
30%
Systemic Therapy
30%
Connective Tissue Cancer
30%
Non Small Cell Lung Cancer
30%
Clinical Trial
27%
Postoperative Care
26%
Immunity
26%
Diseases
23%
Arm
22%
Numbers Needed to Treat
20%
Neoplasm
19%
T Cell
18%
Oncologist
17%
Symptom Assessment
15%
Neoadjuvant Chemotherapy
15%
Gastrointestinal Cancer
15%
Biological Marker
13%
Antigen Presentation
12%
Immune Response
12%
Proportional Hazards Model
11%
Adverse Effect
10%
Hematology
10%
Cytotoxic Chemotherapy
10%
Spine
10%
Targeted Therapy
10%
Ipilimumab
10%
Excitement
10%
The Cancer Genome Atlas
8%
Bladder
8%
Emergency Care
7%
Study Participant
7%